Clinical Trial Update: Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males [Phase 2]

View source ↗

Summary

Results from a Phase 2 trial evaluating the safety, tolerability and acceptability of long-acting cabotegravir for HIV prevention in adolescent males have been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• APRETUDE (CABOTEGRAVIR)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 2 | Status: COMPLETED | Results posted: 2025-01-29